MMMarc Richard Moon

Marc Richard Moon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marc Richard Moon has a total of 184 co-authors. Here are the top co-authors by number of shared publications:

  • Michael K. Pasque

    Division of Cardiothoracic Surgery, Washington University School of Medicine, Saint Louis, Missouri

    7 shared publications
  • Puja Kachroo

    7 shared publications
  • Ralph J. Damiano

    Department of Surgery, Division of Cardiothoracic Surgery, Barnes‐Jewish Hospital Washington University School of Medicine St. Louis Missouri USA

    7 shared publications
  • Hersh S. Maniar

    Division of Cardiothoracic Surgery, Washington University School of Medicine, Saint Louis, Missouri

    5 shared publications
  • Jennifer S. Lawton

    Division of Cardiothoracic Surgery, Department of Surgery, Washington University in St. Louis, St. Louis, Missouri

    5 shared publications
  • Stephen D. Waterford

    Division of Cardiothoracic Surgery, Department of Surgery, SUNY Upstate Medical University, Syracuse, NY

    5 shared publications

Latest Publications

  • Open Access

    Impact of Operative Strategies for Acute Type A Aortic Dissection Over Four Decades

    by Puja Kachroo, Mehran Rahimi, Alexander Angelo Brescia, Nicholas Thomas Kouchoukos, Tsuyoshi Kaneko, Marc Richard Moon

  • Between a Split and a Substitute

    by Anna H. Xue, Marc R. Moon

  • Diversity in cardiothoracic surgery: are we making progress?

    by Marc R. Moon

    Diversity in cardiothoracic surgery will not occur passively. It requires a concerted effort. Historically, cardiothoracic surgery has been one of the least diverse specialties in medicine. The first woman was certified by the American Board of Thoracic Surgery in the early 1960s, nearly one-half century after the specialty was established, but progress from there continued slow. It took another 20 years before the number of women cardiothoracic surgeons exceeded one dozen. More recent efforts by leaders in the specialty have focused on making the specialty more attractive to women with a view towards making cardiothoracic training seem normal, regardless of the trainee’s gender. Diversifying any specialty begins with recruitment, mentorship, support, and finally sponsorship to cultivate future leaders with merit-based promotion. These principles are not only applicable for gender diversity but also for racial and ethnic diversity. The American Association for Thoracic Surgery Medical Student Diversity Scholarship exemplifies a concerted effort to encourage diversity in cardiothoracic surgery. Early reports from this program are encouraging and demonstrate the potential outcome of a group committed to taking action and making a long-term positive change.


  • Open Access

    How we do it: Biatrial maze

    by Marc R. Moon, Puja Kachroo


  • Open Access

    Distal Extent of Resection in Type A Dissection: Keeping It Simple

    by Marc R. Moon, Puja Kachroo

    Type A aortic dissection is a surgical emergency that most cardiac surgeons working with adult patients must manage. Tertiary centers of excellence or aortic reference centers offer some relief to the general cardiac surgeon who may address aortic pathologies only rarely, but there are always patients who cannot be transferred and must be treated at the center of initial presentation. In recent years, experienced aortic surgeons have supported a more aggressive approach to the distal extent of resection. In most circumstances, however, a “simple” approach is appropriate to best ensure operative survival, and patient adherence to optimal medical therapy postoperatively reduces the need for late reoperation on the remaining aorta.The most important goal of surgical treatment in acute type A aortic dissection is to address the impending causes of early death from aortic rupture with tamponade, coronary malperfusion, severe aortic regurgitation with left ventricular failure, and distal malperfusion with end-organ compromise. Secondary goals addressing the distal extent of resection include resecting the primary tear, when visible, and restoring distal true lumen flow to eliminate or limit false lumen flow. These factors contribute to positive remodeling of the distal aorta and decrease the risk of chronic descending and thoracoabdominal aneurysm formation as well as the need for subsequent reoperation. An approach to the treatment of aortic dissection has previously been outlined, noting that each patient is unique.1 Each surgeon and surgical center is also unique regarding their experience with aortic surgery. Often, the best approach for general cardiac surgeons is to “get in and get out” to save the life of the patient, leaving complex distal reconstructions, if needed, to more experienced centers.2 Drs Ouzounian and David3 from Toronto note that “the general cardiac surgeon with limited aortic experience should perform the standard operation and save the patient's life.” Dr Coselli4 has also concluded that, “In this intrinsically complex disease, survival is the most important outcome”—more so than avoidance of or preparation for a second intervention. The selected operative approach should reflect the surgeon's experience because extending the operation beyond one's level of expertise can substantially increase risks of morbidity and mortality. This article focuses on a reproducible approach to the extent of distal resection and reviews the pros and cons of extending the resection beyond the hemiarch.Outcomes with resection of the ascending aorta only vs outcomes with the hemiarch have previously been examined.5-8 Rates of operative survival were similar, but the risk of late reoperation appeared to be lower with the hemiarch replacement strategy,5,6 especially for anterior reoperation for dilation of the residual ascending aorta or arch, which was more common in patients undergoing ascending aorta replacement only (8% of survivors) than in patients undergoing hemiarch replacement (0% of survivors).5 Distal late reoperation was most common in patients with an unresected primary tear, a connective tissue disorder, elevated systolic blood pressure (SBP) at late follow-up, and who were not taking a β-blocker.7 Aortic reoperation at 10 years was necessary in 8% of patients with an SBP lower than 120 mm Hg at late follow-up compared with 26% of patients with an SBP between 120 mm Hg and 140 mm Hg and 51% of patients with an SBP greater than 140 mm Hg (P < .001). Reoperation was necessary in 43% of patients not taking a β-blocker compared with 14% of patients taking a β-blocker (P < .001).8Sixty-nine patients were followed-up with serial computed tomography (CT) imaging to evaluate aortic growth and false lumen patency.7 A total of 412 scans were reviewed, with a mean (SD) value of 6 (5) scans per patient (range, 2-25). The mean (SD) time interval between scans was 10.6 (16.6) months, with a mean (SD) follow-up period of 6.5 (5.5) years. The median (SD) late aortic growth rate was 1.8 (0.8) mm per year in the proximal descending aorta, 1.6 (2.6) mm per year at the diaphragmatic hiatus, and 1.3 (0.6) mm per year in the abdominal aorta. Though most patients (51%) did not demonstrate substantial aortic growth during follow-up, aortic growth was noted in 18% of successive CT scans in patients whose residual aortas did grow. The onset of growth was unpredictable, occurring most often after the first postoperative year. The mean (SD) postoperative time period for identified aortic growth was 59 (45) months (range, 1-167). Independent predictors of late growth were greater initial aortic diameters, patent false lumen (in 67% of patients), and elevated SBP at late follow-up.An important question in the postoperative period is which time interval is most appropriate for serial CT imaging. Findings suggest that the interval should be individualized based on the size of the residual dissected aorta.7Table I demonstrates that if the residual aorta is smaller than 3.5 cm, growth is present in only 5% of scans performed at a 6-month interval compared with 21% of scans performed at a 12-month interval, so in patients with small aortas, yearly imaging is sufficient. In contrast, if the residual aorta is larger than 5.0 cm, growth is demonstrated in 34% of scans performed at 6-month intervals and in 83% of scans performed at 12-month intervals. More frequent imaging is likely appropriate in patients with aortas larger than 5.0 cm, especially once growth on serial examinations has been documented.Dr Coselli from Baylor College of Medicine4,9 has summarized his conservative approach to distal resection in acute type A dissections. His group extended resection to the aortic arch in 7% of patients, an approach that was associated with increased circulatory arrest, cardiopulmonary bypass time, and myocardial ischemia times.9 A...


  • Open Access

    Leveraging Innovation to Mitigate Risk During Heart Surgery

    by Marc R. Moon, Puja Kachroo

    Innovation is not necessarily about the “next big thing” according to Mehta.1 Instead, innovation can occur by combining existing technologies, developing small ideas that compound, or evolving to address problems that have arisen from previous innovations that yielded unpredictable consequences. Innovation in the field of cardiovascular surgery is no different. As the field becomes progressively less invasive through innovation, patients who require open cardiac surgery are increasingly complex and carry increased risk. Patients with ischemic cardiomyopathy at high risk for morbidity often require surgical revascularization and valve interventions; however, risk factors such as diminished ejection fraction, redo operation, and multiple comorbidities compound perioperative morbidity and operative mortality. This report will define high-risk cardiac surgery and discuss how surgeons can leverage innovation to mitigate risk.The Surgical Treatment for Ischemic Heart Failure (STICH) trial randomized 1,212 patients with left ventricular ejection fraction (LVEF) of 35% or less and coronary artery disease suitable for surgical revascularization to coronary artery bypass grafting (CABG) or guideline-directed medical therapy (GDMT).2 There was some crossover, but the initial analysis was done based on intention to treat. Among the 610 patients who were randomly assigned to the CABG group, 555 (91.0%) underwent CABG before completion of the trial. Among the 602 patients who were randomly assigned to the medical therapy group, 119 (19.8%) underwent CABG at any time before the completion of long-term follow-up. At median follow-up of 9.8 years, the CABG group had significantly lower risk of death from any cause with a hazard ratio (HR) of 0.84 (95% CI, 0.73–0.97, P = .02) as well as lower risk of death from cardiovascular cause (P = .006), hospitalization for heart failure (P = .002), nonfatal myocardial infarction (MI) (P = .03), or nonfatal stroke (P = .03) (Fig. 1).2 The results remained consistent following analysis of crossovers. Of all patients who ultimately underwent CABG, 57% died during follow-up compared with 68% of those who underwent GDMT alone (HR, 0.75; 95% CI, 0.65–0.87; P < .001). The number needed to treat was 14 to save 1 life over 10 years with CABG.Sun and coauthors3 reviewed 12,113 patients with LVEF less than 35% and coronary disease appropriate for surgical revascularization who underwent percutaneous coronary intervention or CABG in Ontario, Canada. Propensity matching yielded 2,397 patients in each group. Patients who underwent percutaneous coronary intervention had significantly higher mortality rates (HR, 1.6; 95% CI, 1.3–1.7), cardiac morbidity (HR, 2.0; 95% CI, 1.9–2.2), repeat revascularization (HR, 3.7; 95% CI, 3.2–4.3), and hospitalization for MI (HR, 3.2; 95% CI, 2.6–3.8) or heart failure (HR, 1.5; 95% CI, 1.3–1.6) than did those who underwent CABG. These 2 studies support an aggressive surgical approach in patients with ischemic cardiomyopathy to improve long-term outcomes. Patients with ischemic cardiomyopathy live longer and have less cardiac morbidity with surgical revascularization. Stable patients with ischemic cardiomyopathy, however, have a higher 30-day mortality rate with CABG than with GDMT alone because of the acute surgical risk (4% vs 1% in STICH).2 Thus, there is a need to explore options to decrease upfront morbidity and mortality in patients who require high-risk cardiac surgical intervention.Use of the Society for Thoracic Surgery risk calculator is often not accurate at the high end of risk for morbidity, especially in patients undergoing reoperative surgery.4 Because of the magnitude of the data sets used to develop modern risk calculators, lesser common but very effective risk factors may be overshadowed by other more common risk factors and not reach statistical significance in multivariate analysis. For example, cirrhosis and liver failure have a profound effect on outcomes of any procedure, but neither is included in most cardiac surgery risk algorithms. In addition, frailty is a more recent addition to the preoperative evaluation of patients to determine fitness for transcatheter procedures; however, it does not affect risk prediction calculators for open procedures. High-risk cardiac surgery must be determined through assessment of a combination of objective and subjective criteria.A survey of cardiac surgeons identified low LVEF as the most important risk factor, followed by elevated EuroSCORE, and redo surgery.5 Elevated creatinine levels, tight left main stenosis with unstable angina, and elevated troponin and brain natriuretic peptide levels were also considered, but to a lesser degree. The Toronto General Hospital group reported a 9% incidence of low cardiac output syndrome (LCOS) among 4,558 patients undergoing CABG.6 Low cardiac output syndrome was defined as the need for intra-aortic balloon pump (IABP) or inotropes for more than 30 minutes postoperatively to maintain a systolic blood pressure greater than 90 mm Hg and a cardiac index greater than 2.2 L/min/m2. The mortality rate was much higher at 17% in those with LCOS than in patients with LCOS (17% vs 0.9%; P < .001). The most important risk factors for LCOS were: (1) LVEF less than 20% (27% incidence of LCOS in these patients; HR, 5.7), (2) reoperative surgery (25%; HR, 4.4), and (3) emergency operation (27%; HR, 3.7). Other significant factors included female sex (16%; HR, 2.5), diabetes (13%; HR, 1.6), age older than 70 years (13%; HR, 1.5), left main coronary artery disease (12%; HR, 1.4), recent MI (16%; HR, 1.4), and triple-vessel disease (10%; HR, 1.3). Strategies for optimization should focus on patients with poor left ventricular (LV) function and those undergoing reoperative surgery.Preoperative assessment of organ dysfunction should be performed. Correction of preoperative anemia may result in fewer blood...


  • Medical Therapy After CABG: the Known Knowns, the Known Unknowns, and the Unknown Unknowns

    by Lauren K. Barron, Marc R. Moon

    Purpose Medical therapies play a central role in secondary prevention after surgical revascularization. While coronary artery bypass grafting is the most definitive treatment for ischemic heart disease, progression of atherosclerotic disease in native coronary arteries and bypass grafts result in recurrent adverse ischemic events. The aim of this review is to summarize the recent evidence regarding current therapies in secondary prevention of adverse cardiovascular outcomes after CABG and review the existing recommendations as they pertain to the CABG subpopulations. Recent Findings There are many pharmacologic interventions recommended for secondary prevention in patients after coronary artery bypass grafting. Most of these recommendations are based on secondary outcomes from trials which include but did not focus on surgical patients as a cohort. Even those designed with CABG in mind lack the technical and demographic scope to provide universal recommendations for all CABG patients. Conclusion Recommendations for medical therapy after surgical revascularization are chiefly based on large-scale randomized controlled trials and meta-analyses. Much of what is known about medical management after surgical revascularization results from trials comparing surgical to non-surgical approaches and important characteristics of the operative patients are omitted. These omissions create a group of patients who are relatively heterogenous making solid recommendations elusive. While advances in pharmacologic therapies are clearly adding to the armamentarium of options for secondary prevention, knowing what patients benefit most from each therapeutic option remains challenging and a personalized approach is still required.